Alumis reports 54% complete skin clearance
Compartilhar
Alumis (NASDAQ:ALMS) reported new Phase 3 ONWARD results for envudeucitinib showing 54% of patients achieved complete skin clearance at Week 48.
Alumis (NASDAQ:ALMS) reported new Phase 3 ONWARD results for envudeucitinib showing 54% of patients achieved complete skin clearance at Week 48.
Alumis (NASDAQ:ALMS) surged as much as 82% in early trading Tuesday after its experimental oral drug, envudeucitinib, outperformed both a placebo and Amgen’s blockbuster Otezla in two Phase 3 trials for moderate-to-severe plaque psoriasis.
Alumis (NASDAQ:ALMS) reported Phase 2b LUMUS trial results for oral TYK2 inhibitor envudeucitinib in moderate-to-severe systemic lupus erythematosus, with the overall study population not meeting the primary endpoint.
